COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist ... and similar expressions are intended to identify ...

EL-22 is leveraging a myostatin-engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

As demand for GLP-1 medications surges, Hydreight’s inclusion of Liraglutide introduces a stable, patent-free, and clinically proven option—ideal for patients and providers seeking consistent ...

Enobosarm, a selective androgen receptor modulator (SARM), is being developed as a next generation drug that makes weight ...

DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R ... terminology (as well as other words or expressions referencing future events ...

EL-22 in Animals: Fusion Protein of Myo-2 for Use in Encouraging Muscle Growth in Animals (Patent Application No. 19/191,246) ...

Stimulating a receptor in adipocytes enhanced energy expenditure and caused sustained weight loss in mice, offering targets ...

What happens to your body after you stop taking Ozempic has been revealed, after the use of weight loss medications has ...

What is our current understanding of how differences in sex can affect obesity prevalence, comorbidities, and treatment ...